Adaptive Biotechnologies Corporation · NASDAQ:ADPT
Adaptive Biotechnologies — JPM 2022 Healthcare Conference
23 slides from Adaptive Biotechnologies's conference presentation, 2022
Slide 1: Powering the Age of Immune Medicine
Powering the Age of Immune Medicine JPM 2022 Healthcare Conference
Slide 2: Safe Harbor
Safe Harbor This presentation has been prepared by Adaptive Biotechnologies Corporation (“we,” “us,” “our,” “Adaptive” or the “Company”) and is made for informational purposes only. The information set forth herein does not purport to be complete or to contain all relevant information. Statements co
Slide 3: T-cells taking center role in immunity to COVID-19
T-cells taking center role in immunity to COVID-19 “Our findings underscore the fact that we need to look at T cells, not just antibodies, if we want a complete picture of the vaccine response for those who have not had COVID-19 and for those who have recovered from the disease,” -E. John Wherry, Ph
Slide 4: Key Catalysts 2022 -- Multiple levers to drive value
Key Catalysts 2022 -- Multiple levers to drive value ◼ T-Detect COVID: Enhance product profile (semi-quant data, correlate of protection) ◼ T-Detect AI: Increase sensitivity/specificity in MS, IBD, RA for market readiness Immune ◼ GNE collaboration: ❑ Advance lead shared candidate to development Med
Slide 5: Using the immune system as the source-code for immune medicine
Using the immune system as the source-code for immune medicine IMMUNE SYSTEM IMMUNE MEDICINE CANCER T Cells GENETICS DATA AUTOIMMUNE INFECTIOUS DISORDERS DISEASES B Cells 5
Slide 6: Business areas of focus
Business areas of focus Immune Medicine MRD Driven by immune receptor data opportunities Driven by clonoSEQ/MRD assay applications TAM ~$48B* TAM ~$6B Drug Discovery Clinical Pharma Cell Therapy Clinical MRD Testing Services Vaccines Testing Pharma * Illustrative TAM for 3 indications for T-Detect (
Slide 7: Immune Medicine
Immune Medicine
Slide 8: Unique ability to map & identify disease specific TCR sequences
Unique ability to map & identify disease specific TCR sequences Pharma Diagnostics Services Immune Medicine Disease Strategy Specific TCR-Antigen Create multiple value Data opportunities stemming from the same core disease data Drug Discovery 8
Slide 9: T-Detect
T-Detect
Slide 10: T-Detect: one blood test that reads T cells to diagnose many diseases
T-Detect: one blood test that reads T cells to diagnose many diseases One Blood Sample Scale TCR- Antigen Map T-Cell Based Diagnostic TCRs COVID-19 Lyme disease Antigens Crohn’s disease Multiple Sclerosis Rheumatoid Arthritis Ovarian cancer 10
Slide 11: T-Detect most advanced indications
T-Detect most advanced indications COVID AUTOIMMUNE LYME Only FDA authorized test Clinical signals in five diseases Study Completed Medicare coverage for Crohn’s, colitis, celiac, MS, RA Lyme season readiness immunocompromised patients 11
Slide 12: T-cells correlate with real world vaccine efficacy
T-cells correlate with real world vaccine efficacy Impact of Variants on Vaccine Response Impact of Variants on Immune Response 100 100 % Activity (Normalized) 75 75 % Efficacy 50 50 25 25 0 0 Original Alpha Beta Delta Original Alpha Beta Delta Omicron From Infection From Symptomatic/Severe Disease
Slide 13: Increasing utility of T-Detect COVID
Increasing utility of T-Detect COVID Correlate of Protection Semi-Quantitative test Value Proposition Inform level of protection Current Offering Monitor level of T-cell response >30K users in 2021 Time & Complexity (2022) 13
Slide 14: Developing T-Detect Autoimmune: a multi-disease blood test
Developing T-Detect Autoimmune: a multi-disease blood test Why Autoimmune Disorders? Advancing multiple signals in parallel All indications at high specificity T- Cells Sensitivity Signal 20-45% 45-70% >70% ◼ Highly disease specific ◼ Mechanistic linkage Ileal Crohn’s confirmed ✓ Colonic Crohn’s ide
Slide 15: Drug Discovery
Drug Discovery
Slide 16: Using the immune system to develop differentiated therapeutics
Using the immune system to develop differentiated therapeutics IMMUNE MEDICINE PLATFORM 3 DRUG MODALITIES THERAPEUTICS T-cell Drug Discovery Therapeutics Antigen T-cell based Vaccines Receptor Novel targets and Antibodies targeting molecules 16
Slide 17: Robust Drug Discovery pipeline
Robust Drug Discovery pipeline 17
Slide 18: MRD
MRD
Slide 19: Our MRD Heme business: synergistic value of pharma and clinical diagnostic
Our MRD Heme business: synergistic value of pharma and clinical diagnostic ◼ Pharma supports lifecycle expansion which drives clinical use MRD ◼ FDA cleared in MM, ALL Clinical Pharma ◼ Broad use among major (BM*) and CLL (BM*, blood) Testing ◼ Clinical usage drives Trials pharma in heme cancer tria
Slide 20: MRD has evolved into an essential clinical decision-making tool
MRD has evolved into an essential clinical decision-making tool MASTER trial Assess response to therapy Escalate/de-escalate therapy Detect relapse early 96% of patients who stopped treatment after two clonoSEQ MRD negative tests did not progress Presented at ASH 2021: “Daratumumab, Carfilzomib, Len
Slide 21: MRD business growth drivers
MRD business growth drivers 400k US patients in active treatments per year 1 Expand Clinical Use Other NHL in blood / plasma* 2 Extend indications & sample types DLBCL (largest NHL subtype) 3 Commercial execution in blood / plasma* MM in blood* ALL in blood* CLL in blood MM in bone marrow ALL in bon
Slide 22: Key Catalysts 2022 -- Multiple levers to drive value
Key Catalysts 2022 -- Multiple levers to drive value ◼ T-Detect COVID: Enhance product profile (semi-quant data, correlate of protection) ◼ T-Detect AI: Increase sensitivity/specificity in MS, IBD, RA for market readiness Immune ◼ GNE collaboration: ❑ Advance lead shared candidate to development Med
Slide 23: Thank You.
Thank You.
Adaptive Biotechnologies — JPM 2022 Healthcare Conference on 6ix